Clinical trial data for the vaccines show they were safe but did not generate enough of an immune response to effectively protect recipients against COVID-19.
While Merck is shelving its two vaccine candidates, the drugmaker said it will keep producing two drugs that treat COVID-19.
The drugmaker is continuing to produce MK-7110, which aims to modulate the respiratory system’s inflammatory response to COVID-19. Merck signed a $356 million agreement with the U.S. government Dec. 23 to supply up to 100,000 doses of MK-7110, and it is also continuing to produce MK-4482, an antiviral drug.
More articles on pharmacy:
FDA approves first monthly injectable to treat HIV
Amazon, Seattle health system create vaccination pop-up site
Premier, Pfizer partner to supply 5 critical drugs
